Radiopharmaceuticals
Development is complex: Usually are highly cancer specific, high persistent expression throughout the tumor and metastasis, readily accessible on the cell surface, not shed and thoroughly validated. Many isotopes are possible and many targets possible such as Nectin4, DLL3, FAP, Somatostatin receptors, PSMA, Integrins, CXCR4, Claudin 18.2, Norepinephrine transporter, EGFR2. Clearance from tumor will matter…